Akari Therapeutics Plc Stock Price, News & Analysis

Akari Therapeutics (Nasdaq: AKTX), a biotechnology firm, announced participation in the Cantor Medical and Aesthetic Dermatology Conference in Miami on December 7-8, 2022. President and CEO Rachelle Jacques will join an ophthalmology panel on December 8, discussing 'Vision for the Future: Dry AMD, Other Greenfield Opportunities, and Late-Stage Stories to Shake Things Up.' The management team will also conduct 1:1 investor meetings to address their pre-clinical program for long-acting PAS-nomacopan in geographic atrophy (GA). Akari's investigational drug, nomacopan, targets autoimmune diseases.

Akari Therapeutics, Plc (Nasdaq: AKTX) announced participation in BTIG's Ophthalmology Day on November 29, 2022, with a fireside chat led by CEO Rachelle Jacques at 9:30 am ET. The company will discuss advancements in long-acting PAS-nomacopan for geographic atrophy (GA), highlighting positive pre-clinical results that may support moving towards IND/IMPD for clinical trials. Akari is focused on developing therapies for autoimmune and inflammatory diseases, with its lead candidate, nomacopan, having received several FDA designations for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.

Akari Therapeutics (Nasdaq: AKTX) announced that the FDA granted Rare Pediatric Disease Designation to its investigational drug, nomacopan, for treating pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). This designation complements the existing Orphan Drug and Fast Track designations. The CEO emphasized the urgent need for effective treatments, highlighting the high mortality rates associated with the condition. The FDA's designation also offers potential benefits, including eligibility for a Priority Review Voucher upon approval of nomacopan.

Akari Therapeutics (Nasdaq: AKTX), a biotechnology firm focused on autoimmune and inflammatory diseases, will attend the Jefferies London Healthcare Conference from November 15-17, 2022. Rachelle Jacques, President and CEO, along with the management team, will hold one-on-one meetings with registered investors. The company is advancing its lead product, nomacopan, which targets severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and is also exploring long-acting formulations for geographic atrophy.

Akari Therapeutics has appointed Dr. John F. Neylan, III, as Executive Vice President and Chief Medical Officer, effective immediately. Dr. Neylan brings over 20 years of experience in medical and clinical development, having previously led research efforts at several biotech firms, including Angion Biomedica and Keryx Biopharmaceuticals. His expertise will support Akari's advancement of nomacopan, currently in a Phase 3 trial for HSCT-TMA, and in pre-clinical research for geographic atrophy. This leadership change aims to strengthen clinical development and accelerate the company’s drug development pipeline.

Akari Therapeutics, Plc (Nasdaq: AKTX) announced its participation in the Sidoti November Virtual Micro-Cap Conference on November 9, 2022, with President and CEO Rachelle Jacques presenting at 1:45 PM Eastern time. The management team will also engage in scheduled 1:1 investor meetings. A recording of the presentation will be available on the company's website post-event. Akari focuses on therapies for autoimmune and inflammatory diseases, particularly its lead asset, investigational nomacopan, which targets complement C5 activation and leukotriene B4 activity.

Akari Therapeutics (Nasdaq: AKTX) received a Nasdaq Listing Qualifications letter stating it is non-compliant with the $1.00 minimum bid price requirement. The company has a 180-day compliance period ending April 24, 2023, to rectify this by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to comply may lead to potential delisting. Currently, there is no immediate effect on trading, and Akari’s shares will continue to trade under the symbol AKTX during this grace period.

Akari Therapeutics has successfully closed a registered direct offering and concurrent private placement, raising approximately $12.8 million. The funds will support the company's focused pipeline, particularly the Phase 3 Part A clinical trial of nomacopan for severe pediatric HSCT-TMA, with data expected in the first half of 2023. The company is also advancing the development of long-acting PAS-nomacopan for geographic atrophy. Despite recent financing success, net loss for Q2 2022 rose to approximately $5.7 million due to increased research and administrative costs.

Akari Therapeutics (Nasdaq: AKTX), a late-stage biotechnology firm focused on therapies for autoimmune diseases, will participate in the Cantor Oncology & HemOnc Conference on September 28, 2022. President and CEO Rachelle Jacques will address challenges in cell therapy during a panel at 9:00 a.m. Eastern time and will engage in 1:1 meetings with investors. Akari’s lead treatment, nomacopan, is under Phase 3 trials for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, along with preclinical work on PAS-nomacopan for geographic atrophy.